LinkedIn Twitter
Founder and Chief Executive Officer of HfS Research, the leading global research analyst organization covering global sourcing strategies. Acclaimed Industry Analyst and Consultant who scribes the leading blog for the services industry "Horses for Sources".  Previously worked  at AMR Research (Gartner Inc),  Deloitte Consulting’s BPO Advisory Services, the  Everest Group and  IDC .  In 2010, Phil was named “IIAR Analyst of the Year” by the Institute of Industry Analyst Relations (IIAR). This is the most coveted global award for industry analysts in technology and services.

One response to “RPA is the gateway drug. AI is the drug…”

  1. Oliver Harris

    Great point Phil, suggesting to keep a ‘critical eye’ so that people can safely stay on the reality side in the hype vs. reality match!
    While embracing the potential of robotic process automation in finance, a wise executive who considers RPA implementation, should also bear in mind its limitations. What am I talking about? Well, consider for instance the need to balance automation with human decision-making ability, or, as Phil also mentions, taking into account the prospected benefits of the use of other emerging technologies like cloud, big data, mobility, etc.
    The CiGen favourite solution to keep your feet on the ground and not fall for the hype, while at the same holding on to the positive facts about automation is “always mull over robotic process automation use cases”.
    Why? Because use cases allow you to learn the steps towards success ‘the easy way’, without having to deal yourself with potentially negative consequences. Peers’ real experiences in use cases provide the most useful learning environment, a sort of second order “learning by doing”, with the additional advantage that it saves you from erring yourself.